000259131 001__ 259131
000259131 005__ 20240112145517.0
000259131 0247_ $$2doi$$a10.1097/WCO.0000000000001172
000259131 0247_ $$2pmid$$apmid:37382114
000259131 0247_ $$2ISSN$$a1350-7540
000259131 0247_ $$2ISSN$$a1473-6551
000259131 0247_ $$2altmetric$$aaltmetric:150753808
000259131 037__ $$aDZNE-2023-00727
000259131 041__ $$aEnglish
000259131 082__ $$a610
000259131 1001_ $$0P:(DE-2719)2000026$$aTeipel, Stefan$$b0$$eFirst author$$udzne
000259131 245__ $$aPredicting cognitive decline in older people by structural and molecular imaging.
000259131 260__ $$bOvid$$c2023
000259131 3367_ $$2DRIVER$$aarticle
000259131 3367_ $$2DataCite$$aOutput Types/Journal article
000259131 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1701347203_30794$$xReview Article
000259131 3367_ $$2BibTeX$$aARTICLE
000259131 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000259131 3367_ $$00$$2EndNote$$aJournal Article
000259131 520__ $$aAvailability of possible disease modifying treatments and the recognition of predementia stages of Alzheimer's disease (AD) have raised awareness for the prognostic and predictive role of biomarkers, particularly imaging markers.The positive predictive value of amyloid PET for the transition to prodromal AD or AD dementia in cognitively normal people is below 25%. Evidence for tau PET, FDG-PET and structural MRI is even more limited. In people with mild cognitive impairment (MCI), imaging markers yield positive predictive values above 60% with moderate advantages for amyloid PET over the other modalities and an added value for the combination of molecular with downstream neurodegeneration markers.In cognitively normal people, imaging is not recommended for individual prognosis due to lack of sufficient predictive accuracy. Such measures should be restricted to risk enrichment in clinical trials. In people with MCI, amyloid PET and, to a somewhat lesser extent, tau PET, FDG-PET, and MRI yield relevant predictive accuracy for clinical counseling as part of a comprehensive diagnostic program in tertiary care units. Future studies should focus on the systematic and patient-centered implementation of imaging markers in evidence-based care-pathways for people with prodromal AD.
000259131 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000259131 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000259131 650_7 $$00Z5B2CJX4D$$2NLM Chemicals$$aFluorodeoxyglucose F18
000259131 650_7 $$2NLM Chemicals$$aBiomarkers
000259131 650_7 $$2NLM Chemicals$$aAmyloid beta-Peptides
000259131 650_7 $$2NLM Chemicals$$atau Proteins
000259131 650_2 $$2MeSH$$aHumans
000259131 650_2 $$2MeSH$$aAged
000259131 650_2 $$2MeSH$$aFluorodeoxyglucose F18
000259131 650_2 $$2MeSH$$aAlzheimer Disease: diagnostic imaging
000259131 650_2 $$2MeSH$$aCognitive Dysfunction: diagnostic imaging
000259131 650_2 $$2MeSH$$aPrognosis
000259131 650_2 $$2MeSH$$aPositron-Emission Tomography: methods
000259131 650_2 $$2MeSH$$aBiomarkers
000259131 650_2 $$2MeSH$$aMolecular Imaging
000259131 650_2 $$2MeSH$$aAmyloid beta-Peptides
000259131 650_2 $$2MeSH$$atau Proteins
000259131 7001_ $$aTang, Yi$$b1
000259131 7001_ $$0P:(DE-2719)9000492$$aBoccardi, Marina$$b2$$eLast author$$udzne
000259131 773__ $$0PERI:(DE-600)2026967-5$$a10.1097/WCO.0000000000001172$$gVol. 36, no. 4, p. 253 - 263$$n4$$p253 - 263$$tCurrent opinion in neurology$$v36$$x1350-7540$$y2023
000259131 909CO $$ooai:pub.dzne.de:259131$$pVDB
000259131 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000026$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000259131 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000492$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000259131 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000259131 9141_ $$y2023
000259131 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-29
000259131 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-29
000259131 915__ $$0StatID:(DE-HGF)0410$$2StatID$$aAllianz-Lizenz$$d2023-08-26$$wger
000259131 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-26
000259131 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-26
000259131 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-26
000259131 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-08-26
000259131 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-26
000259131 915__ $$0StatID:(DE-HGF)1120$$2StatID$$aDBCoverage$$bBIOSIS Reviews Reports And Meetings$$d2023-08-26
000259131 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-26
000259131 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCURR OPIN NEUROL : 2022$$d2023-08-26
000259131 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-26
000259131 9201_ $$0I:(DE-2719)5000062$$kAG Boccardi$$lImplementation Neuroscience$$x0
000259131 9201_ $$0I:(DE-2719)1510100$$kAG Teipel$$lClinical Dementia Research (Rostock /Greifswald)$$x1
000259131 980__ $$ajournal
000259131 980__ $$aVDB
000259131 980__ $$aI:(DE-2719)5000062
000259131 980__ $$aI:(DE-2719)1510100
000259131 980__ $$aUNRESTRICTED